AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca’s recent clinical study update focuses on evaluating the efficacy and safety of Selumetinib in combination with Docetaxel for patients with KRAS mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Officially titled ‘SELECT 1,’ the study aims to provide a second-line treatment option for this specific patient group, assessing progression-free survival, overall survival, and other key outcomes.
The intervention involves administering Selumetinib, an oral drug, alongside Docetaxel, an intravenous chemotherapy agent, to target KRAS mutations in NSCLC. This combination is compared against a placebo with Docetaxel to evaluate its effectiveness.
The study is designed as a Phase III, double-blind, randomized, placebo-controlled trial with a parallel intervention model. It employs quadruple masking to ensure unbiased results, focusing primarily on treatment efficacy.
Key dates include the study’s start on September 25, 2013, with primary results first submitted on February 27, 2017. The latest update was submitted on August 13, 2025, indicating ongoing analysis and data collection.
This update could influence AstraZeneca’s stock performance by potentially enhancing investor confidence if the results show significant efficacy. The study’s progress also positions AstraZeneca competitively within the oncology market, especially against other firms targeting KRAS mutations.
The study is ongoing, with further details available on the ClinicalTrials portal.